Acquired von Willebrand syndrome: from diagnosis to treatment
Acquired von Willebrand syndrome is a rare bleeding disorder, which has been related in various diseases including lymphoproliferative disorders or autoimmune diseases. Its diagnosis is an important step before treatment of patients and particularly in case of bleeding. We report four cases from Cae...
Gespeichert in:
Veröffentlicht in: | Pathologie biologie (Paris) 2009-11, Vol.57 (7-8), p.536-542 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | fre |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 542 |
---|---|
container_issue | 7-8 |
container_start_page | 536 |
container_title | Pathologie biologie (Paris) |
container_volume | 57 |
creator | Bustany, S Gautier, P Lequerrec, A Troussard, X Ollivier, Y Borel-Derlon, A |
description | Acquired von Willebrand syndrome is a rare bleeding disorder, which has been related in various diseases including lymphoproliferative disorders or autoimmune diseases. Its diagnosis is an important step before treatment of patients and particularly in case of bleeding. We report four cases from Caen Hemophilia Treatment Center, diagnosed and treated from 1999 to 2008. Mucocutaneous bleeds in every case were the same as in hereditary von Willebrand disease. All patients had no personal or family history of bleeding. Phenotype was identified as type 2 von Willebrand disease with a loss of high molecular weight multimers. Anti-von Willebrand factor inhibitor screening was positive for three patients. The etiological diagnosis was one chronic lymphocytic leukaemia, two monoclonal gammapathies of undetermined significance (MGUS) and one undetermined case. The management of patients need two stages: first infusions of factor von Willebrand/factor VIII concentrates to stop bleeds, then treatment of the underlying disease such as chemotherapy, corticotherapy and treatment with high doses of polyvalents immunoglobulins. In every case, treatment was effective and improved patient's quality of life. |
doi_str_mv | 10.1016/j.patbio.2008.11.005 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_734142464</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734142464</sourcerecordid><originalsourceid>FETCH-LOGICAL-p140t-fae4934860023ecdc488b5a19be4bf4f05d200d509da724dcec715a3c65283623</originalsourceid><addsrcrecordid>eNo1j01LwzAYx4Mgbk6_gUhunlrzNGmbCh7G8GUw2EXxWNLkqWS0TZekwr69Befpd_nxfyHkDlgKDIrHQzqq2FiXZozJFCBlLL8gSygLmXAAsSDXIRwYgxIEXJEFVFBxUckleV7r42Q9GvrjBvpluw4brwZDw2kw3vX4RNsZ1Fj1PbhgA42ORo8q9jjEG3LZqi7g7Zkr8vn68rF5T3b7t-1mvUtGECwmrUIx98mCsYyjNlpI2eQKqgZF04qW5WYebnJWGVVmwmjUJeSK6yLPJC8yviIPf7mjd8cJQ6x7GzR2nRrQTaEuuQCRiULM5v3ZnJoeTT162yt_qv8f818Jolfj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734142464</pqid></control><display><type>article</type><title>Acquired von Willebrand syndrome: from diagnosis to treatment</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bustany, S ; Gautier, P ; Lequerrec, A ; Troussard, X ; Ollivier, Y ; Borel-Derlon, A</creator><creatorcontrib>Bustany, S ; Gautier, P ; Lequerrec, A ; Troussard, X ; Ollivier, Y ; Borel-Derlon, A</creatorcontrib><description>Acquired von Willebrand syndrome is a rare bleeding disorder, which has been related in various diseases including lymphoproliferative disorders or autoimmune diseases. Its diagnosis is an important step before treatment of patients and particularly in case of bleeding. We report four cases from Caen Hemophilia Treatment Center, diagnosed and treated from 1999 to 2008. Mucocutaneous bleeds in every case were the same as in hereditary von Willebrand disease. All patients had no personal or family history of bleeding. Phenotype was identified as type 2 von Willebrand disease with a loss of high molecular weight multimers. Anti-von Willebrand factor inhibitor screening was positive for three patients. The etiological diagnosis was one chronic lymphocytic leukaemia, two monoclonal gammapathies of undetermined significance (MGUS) and one undetermined case. The management of patients need two stages: first infusions of factor von Willebrand/factor VIII concentrates to stop bleeds, then treatment of the underlying disease such as chemotherapy, corticotherapy and treatment with high doses of polyvalents immunoglobulins. In every case, treatment was effective and improved patient's quality of life.</description><identifier>EISSN: 1768-3114</identifier><identifier>DOI: 10.1016/j.patbio.2008.11.005</identifier><identifier>PMID: 19193498</identifier><language>fre</language><publisher>France</publisher><subject>Age of Onset ; Aged ; Factor VIII - analysis ; Female ; Hemorrhage - etiology ; Hemostasis ; Humans ; Male ; Middle Aged ; Paraproteinemias - complications ; Phenotype ; Prothrombin Time ; von Willebrand Disease, Type 2 - etiology ; von Willebrand Disease, Type 2 - immunology ; von Willebrand Disease, Type 2 - therapy ; von Willebrand Factor - analysis ; von Willebrand Factor - genetics ; von Willebrand Factor - immunology</subject><ispartof>Pathologie biologie (Paris), 2009-11, Vol.57 (7-8), p.536-542</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19193498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bustany, S</creatorcontrib><creatorcontrib>Gautier, P</creatorcontrib><creatorcontrib>Lequerrec, A</creatorcontrib><creatorcontrib>Troussard, X</creatorcontrib><creatorcontrib>Ollivier, Y</creatorcontrib><creatorcontrib>Borel-Derlon, A</creatorcontrib><title>Acquired von Willebrand syndrome: from diagnosis to treatment</title><title>Pathologie biologie (Paris)</title><addtitle>Pathol Biol (Paris)</addtitle><description>Acquired von Willebrand syndrome is a rare bleeding disorder, which has been related in various diseases including lymphoproliferative disorders or autoimmune diseases. Its diagnosis is an important step before treatment of patients and particularly in case of bleeding. We report four cases from Caen Hemophilia Treatment Center, diagnosed and treated from 1999 to 2008. Mucocutaneous bleeds in every case were the same as in hereditary von Willebrand disease. All patients had no personal or family history of bleeding. Phenotype was identified as type 2 von Willebrand disease with a loss of high molecular weight multimers. Anti-von Willebrand factor inhibitor screening was positive for three patients. The etiological diagnosis was one chronic lymphocytic leukaemia, two monoclonal gammapathies of undetermined significance (MGUS) and one undetermined case. The management of patients need two stages: first infusions of factor von Willebrand/factor VIII concentrates to stop bleeds, then treatment of the underlying disease such as chemotherapy, corticotherapy and treatment with high doses of polyvalents immunoglobulins. In every case, treatment was effective and improved patient's quality of life.</description><subject>Age of Onset</subject><subject>Aged</subject><subject>Factor VIII - analysis</subject><subject>Female</subject><subject>Hemorrhage - etiology</subject><subject>Hemostasis</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Paraproteinemias - complications</subject><subject>Phenotype</subject><subject>Prothrombin Time</subject><subject>von Willebrand Disease, Type 2 - etiology</subject><subject>von Willebrand Disease, Type 2 - immunology</subject><subject>von Willebrand Disease, Type 2 - therapy</subject><subject>von Willebrand Factor - analysis</subject><subject>von Willebrand Factor - genetics</subject><subject>von Willebrand Factor - immunology</subject><issn>1768-3114</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j01LwzAYx4Mgbk6_gUhunlrzNGmbCh7G8GUw2EXxWNLkqWS0TZekwr69Befpd_nxfyHkDlgKDIrHQzqq2FiXZozJFCBlLL8gSygLmXAAsSDXIRwYgxIEXJEFVFBxUckleV7r42Q9GvrjBvpluw4brwZDw2kw3vX4RNsZ1Fj1PbhgA42ORo8q9jjEG3LZqi7g7Zkr8vn68rF5T3b7t-1mvUtGECwmrUIx98mCsYyjNlpI2eQKqgZF04qW5WYebnJWGVVmwmjUJeSK6yLPJC8yviIPf7mjd8cJQ6x7GzR2nRrQTaEuuQCRiULM5v3ZnJoeTT162yt_qv8f818Jolfj</recordid><startdate>200911</startdate><enddate>200911</enddate><creator>Bustany, S</creator><creator>Gautier, P</creator><creator>Lequerrec, A</creator><creator>Troussard, X</creator><creator>Ollivier, Y</creator><creator>Borel-Derlon, A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200911</creationdate><title>Acquired von Willebrand syndrome: from diagnosis to treatment</title><author>Bustany, S ; Gautier, P ; Lequerrec, A ; Troussard, X ; Ollivier, Y ; Borel-Derlon, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p140t-fae4934860023ecdc488b5a19be4bf4f05d200d509da724dcec715a3c65283623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2009</creationdate><topic>Age of Onset</topic><topic>Aged</topic><topic>Factor VIII - analysis</topic><topic>Female</topic><topic>Hemorrhage - etiology</topic><topic>Hemostasis</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Paraproteinemias - complications</topic><topic>Phenotype</topic><topic>Prothrombin Time</topic><topic>von Willebrand Disease, Type 2 - etiology</topic><topic>von Willebrand Disease, Type 2 - immunology</topic><topic>von Willebrand Disease, Type 2 - therapy</topic><topic>von Willebrand Factor - analysis</topic><topic>von Willebrand Factor - genetics</topic><topic>von Willebrand Factor - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bustany, S</creatorcontrib><creatorcontrib>Gautier, P</creatorcontrib><creatorcontrib>Lequerrec, A</creatorcontrib><creatorcontrib>Troussard, X</creatorcontrib><creatorcontrib>Ollivier, Y</creatorcontrib><creatorcontrib>Borel-Derlon, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Pathologie biologie (Paris)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bustany, S</au><au>Gautier, P</au><au>Lequerrec, A</au><au>Troussard, X</au><au>Ollivier, Y</au><au>Borel-Derlon, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acquired von Willebrand syndrome: from diagnosis to treatment</atitle><jtitle>Pathologie biologie (Paris)</jtitle><addtitle>Pathol Biol (Paris)</addtitle><date>2009-11</date><risdate>2009</risdate><volume>57</volume><issue>7-8</issue><spage>536</spage><epage>542</epage><pages>536-542</pages><eissn>1768-3114</eissn><abstract>Acquired von Willebrand syndrome is a rare bleeding disorder, which has been related in various diseases including lymphoproliferative disorders or autoimmune diseases. Its diagnosis is an important step before treatment of patients and particularly in case of bleeding. We report four cases from Caen Hemophilia Treatment Center, diagnosed and treated from 1999 to 2008. Mucocutaneous bleeds in every case were the same as in hereditary von Willebrand disease. All patients had no personal or family history of bleeding. Phenotype was identified as type 2 von Willebrand disease with a loss of high molecular weight multimers. Anti-von Willebrand factor inhibitor screening was positive for three patients. The etiological diagnosis was one chronic lymphocytic leukaemia, two monoclonal gammapathies of undetermined significance (MGUS) and one undetermined case. The management of patients need two stages: first infusions of factor von Willebrand/factor VIII concentrates to stop bleeds, then treatment of the underlying disease such as chemotherapy, corticotherapy and treatment with high doses of polyvalents immunoglobulins. In every case, treatment was effective and improved patient's quality of life.</abstract><cop>France</cop><pmid>19193498</pmid><doi>10.1016/j.patbio.2008.11.005</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1768-3114 |
ispartof | Pathologie biologie (Paris), 2009-11, Vol.57 (7-8), p.536-542 |
issn | 1768-3114 |
language | fre |
recordid | cdi_proquest_miscellaneous_734142464 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Age of Onset Aged Factor VIII - analysis Female Hemorrhage - etiology Hemostasis Humans Male Middle Aged Paraproteinemias - complications Phenotype Prothrombin Time von Willebrand Disease, Type 2 - etiology von Willebrand Disease, Type 2 - immunology von Willebrand Disease, Type 2 - therapy von Willebrand Factor - analysis von Willebrand Factor - genetics von Willebrand Factor - immunology |
title | Acquired von Willebrand syndrome: from diagnosis to treatment |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T05%3A17%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acquired%20von%20Willebrand%20syndrome:%20from%20diagnosis%20to%20treatment&rft.jtitle=Pathologie%20biologie%20(Paris)&rft.au=Bustany,%20S&rft.date=2009-11&rft.volume=57&rft.issue=7-8&rft.spage=536&rft.epage=542&rft.pages=536-542&rft.eissn=1768-3114&rft_id=info:doi/10.1016/j.patbio.2008.11.005&rft_dat=%3Cproquest_pubme%3E734142464%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734142464&rft_id=info:pmid/19193498&rfr_iscdi=true |